|Bid||36.23 x 1300|
|Ask||36.98 x 1000|
|Day's Range||35.15 - 36.76|
|52 Week Range||22.22 - 73.90|
|Beta (3Y Monthly)||3.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.94|
The three pure-play CRISPR stocks have been on the decline since early 2018. Shares of Intellia Therapeutics (NTLA), Editas Medicine (EDIT) and leader CRISPR Therapeutics (CRSP) have magnified the declines of the broader stock indexes late last year. Warning! GuruFocus has detected 3 Warning Signs with NTLA.
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.
CRISPR Therapeutics shares moved sharply higher after the FDA Fast Tracked the company's gene therapy targeting beta thalassemia.
Both patients’ cancers had relapsed before the start of the trial. One has multiple myeloma, and the other has sarcoma, Penn Medicine representative John Infanti said in an email. Funding for the trial is provided by Sean Parker’s Parker Institute for Cancer Immunotherapy and private firm Tmunity Therapeutics, he said.
CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the treatment of transfusion-dependent beta thalassemia (TDT). The FDA’s Fast Track program is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill unmet medical needs. A drug granted Fast Track Designation may be eligible for several benefits, including more frequent meetings and communications with the FDA and, if relevant criteria are met, the potential for Accelerated Approval, Priority Review or Rolling Review of a Biologics License Application (BLA).
Earlier this week, the Global X Genomics & Biotechnology ETF (Nasdaq: GNOM) debuted, giving investors a new avenue for tapping the fast-growing genomics market. GNOM tracks the Solactive Genomics Index ...
ZUG, Switzerland and CAMBRIDGE, Mass., April 01, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
Investment scams are nothing new. But since the dot-com bust of 2000, most investors have been able to spot the most egregious, misleading of corporate pitches.That's what's made the Theranos debacle such a shock. The blood-testing company looked, felt and sounded like the real deal. CEO Elizabeth Holmes seemed remarkably credible too… credible enough that insurers, pharmacies and grocery stores were all willing to partner with Theranos.The whole thing, however, was an incredible scam. The company's blood-based tests, as it turns out, couldn't do what Holmes had for years claimed they could. Their results were misleading at best and dangerously wrong at worst. Theranos is no defunct.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNot surprisingly, Theranos' scandal has made investors skeptical of many similar diagnostic companies. * 7 Reasons to Buy Housing Stocks in 2019 That need not be the case, however. Theranos was the exception to the norm rather than the norm. There are many legitimate diagnostic companies, and one area that's seeing a huge boom is genomic testing. Genomic testing stocks belong to companies that look a person's -- or cancer's -- specific gene sequence in order to diagnose and treat patients. Here's a look at eight of the best of them. Exact Sciences (EXAS)Source: Shutterstock Exact Sciences (NASDAQ:EXAS) is committed to treating cancer by spotting it before it forms. Through its partnership with the Mayo Clinic, the company has developed diagnostic tools that can spot concerning colon cancer biomarkers from even the smallest DNA samples, identifying how vulnerable a particular person may be to cancer. In fact, you may be more familiar with the company than you realize. Exact Sciences is the name behind Cologuard, the colon-cancer screener that can be used at home rather than at a doctor's office of medical lab.Exact Sciences isn't yet profitable, but it's also not stopping at colon cancer. It's also working on screening tests that could identify liver, lung, breast and pancreatic cancers. More marketable tests means more revenue, which pushes the company closer to profitability. Genomic Health (GHDX)Source: Shutterstock Genomic Health (NASDAQ:GHDX) is arguably one of the quintessential genomic testing stocks. The company's Oncotype IQ tests allow doctors and caregivers to look at the specific nuances of a particular patient's cancer and tailor a specific treatment plan for that individual. More important, it works. And the medical community believes in what the company brings to the table.At this week's Gallen International Breast Cancer Conference, Dr. Joseph Gligorov of the Breast Cancer Expert Center at the APHP-Tenon Hospital in Paris commented:"The practice-changing precision made possible by such a test can lead to improved quality of care and survival among breast cancer patients, as well as reduced waste of healthcare resources by directing chemotherapy only to patients who have a high likelihood of deriving substantial benefit." * 3 Gold Stocks That Should Glitter With Rising Gold Prices So far the Oncotype battery is limited to breast, prostate and colon cancers, but more forms of cancer are on the radar. In the meantime, Genomic Health continues to refine its existing, proven tests. Sarepta Therapeutics (SRPT)Source: Shutterstock Sarepta Therapeutics (NASDAQ:SRPT) isn't exactly at home in a list of genomic testing stocks in that it's actually the developer of a treatment for Duchenne muscular dystrophy. Its therapy is gene-based, however, making the company more than relevant to investors that believe in the power of gene therapy. Its core product is Exondys 51 -- an injection that can cause a cell to 'skip' a faulty exon in RNA when replicating itself, restoring dystrophin production to functional levels. Dystrophin is a protein needed to make muscles function properly.Sarepta isn't stopping there, however. It's also working on an LGMD gene therapy that Janney analyst Yun Zhong has high hopes for. Zhong, in fact, believes Sarepta could double the size of the exon-skipping market by 2020. Crispr Therapeutics (CRSP)Source: Shutterstock Fans and followers of biotech developments have almost certainly heard the term 'CRISPR,' which is short for 'clustered regularly interspaced short palindromic repeats.' It's a family of DNA sequences that allow researchers and drug developers to manipulate longer spans of genetic material rather than repair one small segment of genetic material. Crispr Therapeutics (NASDAQ:CRSP) is one of the names that helped usher in the new way of thinking about gene-editing. Like Sarepta Therapeutics, it's arguably a little out of place in a look at genomic testing stocks to consider. But the biopharma outfit represents the best of the potential the industry sees for itself as it learns more about how DNA works (and doesn't work). * 10 Tech Stocks With Key Products That Face an Uncertain Future Crispr Therapeutics has already put the idea to good use too. Its pipeline includes treatments for hemoglobinopathies, some cancers, diabetes and other genetic diseases. InVitae (NVTA)InVitae (NYSE:NVTA) isn't exactly a household name, but perhaps someday it will be. The company makes a variety of genomics-based tests that help patients pinpoint potential problem ranging from heart trouble to cancer risks to neurological issues, just to name a few.And customers are buying them up, in spades. Last quarter's top line was up a whopping 117% year-over-year, with unit sales growing more than 100%.InVitae is still logging losses, but they're shrinking, and they're improving at an increasingly faster clip. This year's projected loss of $1.78 per share is only modestly better than last year's loss of $1.94 per share of NVTA stock. But, that loss is expected to be whittled down to only $1.15 per share next year -- on strong double-digit sales growth.InVitae is arguably the name investors are errantly looking past. Illumina (ILMN)Source: Flickr Whereas InVitae is the red-hot name few people have heard of, Illumina (NASDAQ:ILMN) is one of the genomic testing stocks most investors have heard of. The $45 billion behemoth is not only the name that's impossible to avoid, it's been largely deemed as the industry's standard-bearer. Illumina, in simplest terms, makes gene-sequencing and array technologies that can be utilized by drug developers or diagnostic companies. It's powering the genomic-testing market forward by empowering others. * Is This Overlooked Marijuana Stock a Buy? It's also, unlike most of its genomic-focused peers, profitable. Last quarter's revenue may have only grown 11% year-over-year. But, that top line of $867 million translated into earnings of $1.32 per share. For the full year, Illumina banked a profit of $5.72, which is expected to swell to $6.53 this year and $7.50 per share next year. Veracyte (VCYT)Source: Shutterstock Veracyte (NASDAQ:VCYT) currently offers three genomic tests. Afirma helps pin down thyroid cancers, Percepta helps doctors take aim at lung cancer and Envisia aids in the diagnosis of idiopathic pulmonary fibrosis. Like InVitae, Veracyte isn't yet profitable. But, also like InVitae, strong sales growth is quickly chipping away at its losses. Last year's loss of 62 cents per share is expected to shrink to a loss of only 41 cents per share of VCYT stock this year, and shrink to only 23 cents per share next year.Real profits are in sight, even if only on the distant horizon. Myriad Genetics (MYGN)Source: Shutterstock Finally, add Myriad Genetics (NASDAQ:MYGN) to a list of genomic testing stocks to consider. Myriad Genetics appropriately offers a myriad of genomic tests that can help patients and doctors look for genetic markers for everything ranging from breast cancer to depression to arthritis and more.And, like Illumina, Myriad Genetics is profitable. The $2.5 billion outfit turned $217 million worth of revenue last quarter, up 15%, into income of $6.1 million. Its hereditary cancer screener led the way. * The 7 Best Penny Stocks to Buy Growth appears to be in the cards too… perhaps much more than most investors fully appreciate. The medical community is fast-becoming a believer in the power of genetic testing, with the American Society of Breast Surgeons now recommending genetic testing for all breast cancer patients. Meanwhile, Medicare now covers Myriad's myPath(r) Melanoma test.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley.Compare Brokers The post 8 Genomic Testing Stocks That Can Ease the Sting of Theranos appeared first on InvestorPlace.
With so much attention pointing once again to the again-escalating U.S.-China trade dispute, it's easy to overlook Bio-Path Holdings (NASDAQ:BPTH). However, the oncology specialist is easily one of the best-performing investments of 2019. Year-to-date, BPTH stock has gained a mind-blowing near-500%.More importantly, a fundamental catalyst supports the dramatic rise in valuation. A favorable clinical trial of the company's acute myeloid leukemia drug lifted Bio-Path stock from the doldrums. This news has obvious positive implications, as this particular cancer has a market size of $701.6 million. Overall, leukemia's market value will likely hit $12 billion in a few years.At the same time, biotechnology firms are hardly stable investments. While BPTH stock currently enjoys the afterglow of a promising trial, it could just as easily go awry. After all, if cancer research was straightforward, we'd already have a cure.InvestorPlace - Stock Market News, Stock Advice & Trading TipsInvariably, though, the skyrocketing Bio-Path stock commands our attention. Should you buy into this winning streak, or is this hand destined to cool? Here are three pros and three cons to consider: Pro 1: A Possible Breakthrough Could Further Boost BPTH StockI'm not breaking new ground when I say that cancer is an uncomfortable subject. However, acute myeloid leukemia is a nasty strain. The disease spreads very rapidly if left untreated. By entering the bloodstream, this cancer can affect the liver, spleen, central nervous system, and testicles. * Top 7 Service Sector Stocks That Will Pay You to Own Them The latter may have caught the attention of Wall Street's men, who fueled the spike in BPTH stock.In all seriousness, though, the latest clinical trial offered encouraging data. Out of 17 patients in the study, 11 responded to Bio-Path's prexigebersen drug. And of those 11, five experienced a complete response. Pro 2: Bio-Path Stock Levers Profound TechnologiesA thousand years from now, I'm sure that our future progeny will look back on us with macabre fascination for how we treated cancer by blasting patients with radiation. I can't help but bring up the obvious question: doesn't radiation cause cancer?Fortunately, much smarter people than I have answered this inquiry. Bio-Path's solution is their proprietary DNAbilize platform. In short, this enables oncologists to precisely deliver cancer-killing therapies to affected cells without nuking the patient.Such technologies lever a broader impact on this industry. Some patients simply don't have the physical strength to endure chemotherapy or radiology. DNAbilize is a lifesaver on multiple fronts, further bolstering the case for Bio-Path stock. Pro 3: BPTH Probably Already Hit Rock-BottomI'm not always comfortable with the argument that a particular stock has priced in all the bad news. Unless you're privy to insider information -- at which point you shouldn't act on that info -- you just don't know if more nasty stuff lies ahead.However, I can't imagine BPTH stock falling even more than it already has. Bear in mind that shares used to trade for well over $500 just a few years ago. With that context, BPTH appears like a bargain, even with this year's mooning. Con 1: Shares Used to Trade at $500-plusOn one hand, the ability to buy Bio-Path stock for pennies on the dollar appeals to many contrarians. But those with a critical eye will argue that a reason exists for the meltdown.Let's look even further back. In early January 2014, BPTH stock was on the cusp of clearing $1,000. In May of 2008, and just prior to the Great Recession, it hit four digits.The argument that "it can't get any worse" failed these early investors "bigly." You don't want to repeat their mistake. Con 2: Bio-Path has Tough CompetitionWhile Bio-Path's DNAbilize platform appears profoundly impressive, it's not the only party in town. BPTH is riding the broader category of gene therapy, or the targeted delivery of disease-fighting therapies. But other names, including CRISPR Therapeutics (NASDAQ:CRSP), Roche Holding (OTCMKTS:RHHBY), and Editas Medicine (NASDAQ:EDIT) compete aggressively in this sector. * 5 Cloud Stocks to Help Your Portfolio Fly Given the historical volatility in BPTH stock, I want some reassuring factors that I can depend on. Unfortunately, Bio-Path doesn't have a moat, which makes me jittery about its sudden rise. Con 3: Biotech is Incredibly VolatileRight now, everyone has mad love for Bio-Path stock because of its unexpected ascent. However, I've seen this story play out before in this wild market segment. All it takes is one bad trial to undo years of effort and research.Plus, BPTH stock has two obstacles regarding its drug pipeline. Management must demonstrate that their therapies can consistently beat placebo, which is no easy task. Plus, they have to show that their solutions are superior to the competition. Again, that's no gimme. Bottom Line on BPTH StockAdmittedly, I see the both the technical and fundamental potential for BPTH, and I'm personally intrigued. However, I keep going back to the inherent volatility of the biotech industry and Bio-Path stock. Yes, it enjoyed a positive paradigm-shift, but it could just as easily go sour.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons appeared first on InvestorPlace.
In addition to high-quality blue chip, long-term holdings, we also occasionally look to long-term opportunities that have the potential to return lottery-sized profits, asserts Jim Powell, editor of Global Changes & Opportunities Report.
Stocks with market capitalization between $2B and $10B, such as CRISPR Therapeutics AG (NASDAQ:CRSP) with a size of US$2.0b, do not attract as much attention from the investing community asRead More...
The biotech industry has been on a tear in 2019, up 25% through the first two months of the year. That's great. But niche gene therapy stocks are performing even better.Source: Shutterstock The rally has been fueled by a strong combination of merger announcements, positive news from the FDA and the continued development of breakthrough therapies. Headlines have been popping up nonstop over the last week, and today I'd like to recap some of the highlights. Spark Therapeutics (NASDAQ:ONCE), a small-cap biotech that focuses on gene therapies, was purchased by pharmaceutical giant Roche (OTCMKTS:RHHBY). On a per-share basis, the $4.8 billion purchase price equated to $114.50 -- a huge 122% premium over ONCE's previous close. Spark investors are now looking at 190% gains in 2019 alone.The same day, CRISPR Therapeutics (NASDAQ:CRSP) announced that human trials had begun for its CTX001 gene therapy drug. A patient suffering from beta-thalassemia had been dosed. And in just a few months, the same drug is expected to be tested on patients with sickle cell disease.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCTX001, which is based on the CRISPR/Cas9 gene editing technique, is currently undergoing Phase I/II trials. Typically, the first dose in such a trial would not be a headline. But this was the first time that CRISPR technology had ever been used on a human. The news sent CRSP up more than 20%. * 7 Top-Rated Stocks to Buy for March A few days later, gene therapy stock Sarepta Therapeutics (NASDAQ:SRPT) released impressive results for its muscular dystrophy drug. And in the same press release it announced the $165 million purchase of privately-held gene therapy company Myonexus. The stock rallied on the news and is now up 34% so far this year. But even with the acquisition news, SRPT has long been rumored as a takeover target for larger pharmaceutical companies.Finally, micro-cap gene therapy stock MeiraGTx Holdings (NASDAQ:MGTX) announced an $80 million private placement. This is important because its lead investor is the private arm of Johnson & Johnson (NYSE:JNJ). MeiraGTx is already up a whopping 67% in 2019. Get in Position for Life-Changing Profits from Gene Therapy StocksThere is absolutely no question that there is money to be made in the gene therapy stocks over the long term. However, because the sector is still in its infancy, we have to expect increased volatility. What we're seeing now is a very strong upswing.Gene therapy is on track to save countless lives. It's also on track to make you life-changing profits as long as you can weather the ups and downs that are simply the nature of early-stage mega-trends.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Retail Stocks Ready to Break Out * 7 Strong Buy Stocks the Street Loves * 10 Best Stocks to Buy and Hold Forever Compare Brokers The post Why NOW Is the Time to Buy Gene Therapy Stocks appeared first on InvestorPlace.
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 27, 2019 -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
Although CRISPR Therapeutics (NASDAQ: CRSP) reported negligible revenue and a loss for the fourth quarter on Monday, the owners of CRSP stock are taking the results in stride.The value of the company is in its gene-editing technology, which is a huge advancement in health sciences. From an investing point of view, CRSP is not going to make any revenue, let alone profits, for the foreseeable future. CRSP stock rallied about 25% on Monday after Roche (OTCQX: RHHBY) agreed to buy CRSP's competitor, Spark Therapeutics (NASDAQ: ONCE) * 7 IPOs to Get Excited for in 2019 Spark Bought OutRoche offered to buy Spark for $114.50 per share in cash for a total price tag of $4.8 billion. This offer is more than double the price at which Spark closed on Friday. The buyout is irrational from a financial point of view because Spark's losses have mounted, according to its latest financial report. Although its revenue rose about 400% to $64.73 million in Q4, it lost $2.11 a share.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSource: Shutterstock With that backdrop in mind, CRSP's losses in the quarter will not worry the owners of CRSP stock because, in the wake of the Roche-Spark deal, they will believe that CRSP could also get acquired. So instead of focusing on the company's financial results, the market may turn its focus to the clinical achievements the firm made in 2018. 2018 HighlightsCRSP, along with its partner Vertex (NASDAQ:VRTX), continued to advance a number of its key programs in 2018. Among the diseases the companies are looking to treat are β-thalassemia, "a blood disorder that reduces the production of hemoglobin," according to the NIH, and sickle cell disease (SCD). CRSP and VRTX are also working on immuno-oncology.In the area of hemoglobin disorders, including β-thalassemia and sickle cell disease, CRISPR treated a patient with its CTX001 , a gene-edited stem cell therapy, for the first time, the company announced on Monday.The patient was treated during a Phase 1/2 study of CTX001 in patients with transfusion-dependent beta thalassemia. At the same time, the companies said they have launched a Phase 1/II trial of patients with severe SCD, and they noted that the first patient with the disease is expected to be infused with CTX001 in the middle of this year. All of the patients participating in both trials will have their own edited hematopoietic stem cells injected into them."Patients will initially be monitored to determine when the edited cells begin to produce mature blood cells, a process known as engraftment," the companies stated.In the area of Immuno-Oncology, CRISPR will start a trial of CTX110, a CAR-T cell therapy, in the first half of 2019. The company will use its gene-editing technique to target blood cancers that arise from B cells. It is worth noting that a preclinical study of CTX120, CRISPR's CAR-T cell therapy for the treatment of multiple myeloma, showed durable cytotoxic capacity.. These results gave the company the positive data it needs to continue its study in patients. Balance Sheet AnalysisInvestors absolutely must review at least the cash position of emerging biotechnology companies. Worth noting when evaluating CRISPR is that its healthy cash and cash equivalents of $456.6 million may mean the company will not need to sell stock to raise cash this year.In Q4, the company spent $28.8 million on R&D, up from $20 million last year. Its R&D spending could increase, depending on the progress of CRISPRs clinical studies. The Valuation of CRSP StockInvestors may only guess what CRSP stock is worth. The addressable market that the company is targeting is very large Using a 10-year DCF Revenue Exit model, if the company's revenue jumps 25% - 100%, CRSP stock is worth over $40 a share.Seven analysts who cover CRSP stock have an average price target that is over 40% above its recent price of around $37, according to Tipranks.As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Consumer Stocks to Buy and Hold for Years * 4 China Stocks Soaring on Trade Hopes * 3 Esports Stocks to Benefit From the Boom Compare Brokers The post CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again appeared first on InvestorPlace.
CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.
Crispr Therapeutics stock popped Monday after the biotech announced it dosed a patient with its gene-editing therapy — making it the first firm to use CRISPR technology in a clinical study.